Market capitalization | $4.83m |
Enterprise Value | $7.48m |
PER (TTM) P/E ratio | negative |
EV/Sales (TTM) EV/Sales | 4.40 |
P/S ratio (TTM) P/S ratio | 2.84 |
P/B ratio (TTM) P/B ratio | 0.23 |
Sales growth (TTM) Sales growth | -21.24% |
Turnover (TTM) Turnover | $1.70m |
EBIT (operating result TTM) EBIT | $-13.95m |
As a free StocksGuide basic user, you can view the scores for all 6,953 shares worldwide.
Jun '23 |
+/-
%
|
||
Turnover | 1.70 1.70 |
21%
21%
|
|
Gross income | 0.85 0.85 |
48%
48%
|
|
EBITDA | - - |
-
|
EBIT (operating result) EBIT | -14 -14 |
7%
7%
|
Net profit | -15 -15 |
9%
9%
|
Figures in millions USD.
If you wish, you can receive an e-mail every morning in time for breakfast containing all the stock news relevant to you.
Anpac Bio-Medical Science Co., Ltd., a development-stage biotechnology company, researches, develops, markets, and sells multi-cancer screening and detection tests to corporations and life insurance companies in the People's Republic of China and the United States. It also manufactures cancer differentiation analysis devices; and offers physical checkup package services. The company was founded in 2010 and is headquartered in Lishui, the People's Republic of China.
Head office | Virgin Islands, British |
CEO | Hao Yu |
Employees | 75 |
Founded | 2010 |
Website | www.anpacbio.com |
StocksGuide is the tool for easily finding, analyzing and monitoring shares. Learn from successful investors and make well-founded investment decisions. We make you a self-determined investor.